EUCTR2005-004460-22-BE进行中（未招募）不适用
Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo nephrotic syndrome due to focal segmental glomerulosclerosis.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Male and female patients aged from 18 to 70 years old
- •2)Patients with initial clinical diagnosis of de novo nephrotic syndrome (i.e. proteinuria > 3 g/d., hypoalbuminemia, hyperlipidemia) and biopsy proven focal segmental glomerulosclerosis.
- •3)Renal function > 50 ml/min. per 1.73 m² body surface area as measured by a 24 hrs. urine creatinine clearance.
- •4)Written informed consent should be obtained from participating patients
- •5)Females of childbearing age should use appropriate contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Current malignancies or history of previous malignancies except for treated basal or squamous cell skin carcinoma.
- •2)Metabolic disorders (including diabetes mellitus patients) or systemic diseases (e.g. lupus,…)
- •3)Active liver diseases
- •4)Presence of another kidney disease
- •5)Disorders of the central nervous system
- •6)The use of immunosuppressive therapy 3 months prior to the start of the study
- •7)Kidney transplanted patients
- •8)Active infection at study entry
- •9)Known hypersensitivity to ACE-inhibitors or contraindication for ACE-inhibitors
- •10)Renal artery stenosis
- •11)Pregnancy or wish to become pregnant during the study period
- •12)Non-compliance or psychological disorders which may impair the compliance of the patient
- •13)HIV positive patients
研究者
相似试验
进行中（未招募）
不适用
Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndrome due to idiopathic membranous glomerulopathyMembranous NephropathyEUCTR2005-004469-40-BEHopital Erasme50
已完成
3 期
Multi-center, open-label, randomized, parallel-group comparison of cycle control, bleeding pattern, lipid and carbohydrate metabolism of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestodene (material no. 80876395) in a 21-day regimen vs. a comparator patch EVRA® (0.6 mg ethinylestradiol and 6 mg norelgestromin) in a 21-day regimen for 7 cycles in 400 womecycluscontrole tijdens anticonceptie gebruikbleedingpatterncyclecontrolNL-OMON33166Bayer Health Care AG140
进行中（未招募）
不适用
Multi-center, open-label, randomized, parallel-group comparison of cycle control, bleeding pattern, lipid and carbohydrate metabolism of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestodene (material no. 80876395) in a 21-day regimen vs. a comparator patch EVRA® (0.6 mg ethinylestradiol and 6 mg norelgestromin) in a 21-day regimen for 7 cycles in 400 women - Transdermal contraceptive patch: EU cycle control study (vs. EVRA)Prevention of pregnancyMedDRA version: 9.1Level: LLTClassification code 10060346Term: Transdermal contraceptionEUCTR2008-007308-27-NLBayer HealthCare AG400
进行中（未招募）
1 期
Multi-center, open-label, randomized, parallel-group comparison of cycle control, bleeding pattern, lipid and carbohydrate metabolism of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestodene (material no. 80876395) in a 21-day regimen vs. a comparator patch EVRA® (0.6 mg ethinylestradiol and 6 mg norelgestromin) in a 21-day regimen for 7 cycles in 400 women - Transdermal contraceptive patch: EU cycle control study (vs. EVRA)EUCTR2008-007308-27-ATBayer HealthCare AG400
进行中（未招募）
不适用
Multi-center, open-label, randomized, parallel-group comparison of cycle control, bleeding pattern, lipid and carbohydrate metabolism of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestodene (material no. 80876395) in a 21-day regimen vs. a comparator patch EVRA® (0.6 mg ethinylestradiol and 6 mg norelgestromin) in a 21-day regimen for 7 cycles in 400 women - Transdermal contraceptive patch: EU cycle control study (vs. EVRA)EUCTR2008-007308-27-CZBayer HealthCare AG400